Q3 EPS Estimate for Revolution Medicines Raised by Analyst

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Stock analysts at Wedbush upped their Q3 2025 earnings per share (EPS) estimates for Revolution Medicines in a note issued to investors on Tuesday, June 24th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of $0.12 for the quarter, up from their previous forecast of ($1.21). Wedbush has a "Outperform" rating and a $73.00 price objective on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines' Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($3.41) EPS, FY2027 earnings at ($3.64) EPS, FY2028 earnings at ($3.10) EPS and FY2029 earnings at $1.97 EPS.

Several other equities research analysts have also weighed in on RVMD. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 target price (down from $73.00) on shares of Revolution Medicines in a research report on Wednesday, May 14th. Guggenheim restated a "buy" rating and set a $80.00 price objective on shares of Revolution Medicines in a research note on Wednesday. Oppenheimer lifted their price objective on shares of Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Stifel Nicolaus cut their price objective on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Finally, Needham & Company LLC restated a "buy" rating and set a $57.00 price objective on shares of Revolution Medicines in a research note on Tuesday. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $67.58.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD opened at $37.48 on Friday. Revolution Medicines has a 1-year low of $29.17 and a 1-year high of $62.40. The business's fifty day moving average price is $39.61 and its two-hundred day moving average price is $40.06. The firm has a market capitalization of $6.98 billion, a PE ratio of -9.37 and a beta of 1.10.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period in the previous year, the business earned ($0.70) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RVMD. Boxer Capital Management LLC acquired a new position in Revolution Medicines during the fourth quarter worth about $187,184,000. Janus Henderson Group PLC grew its holdings in Revolution Medicines by 54.5% during the fourth quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock worth $414,777,000 after acquiring an additional 3,346,755 shares during the period. Lunate Capital Ltd acquired a new position in Revolution Medicines during the first quarter worth about $77,658,000. Vanguard Group Inc. grew its holdings in Revolution Medicines by 14.7% during the fourth quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company's stock worth $747,799,000 after acquiring an additional 2,185,082 shares during the period. Finally, Farallon Capital Management LLC grew its holdings in Revolution Medicines by 17.1% during the fourth quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock worth $579,498,000 after acquiring an additional 1,931,000 shares during the period. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.